title: Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats.
abstract: The effect of the grapefruit flavonoid naringin, an inhibitor of CYP3A4, on the pharmacokinetics of quinine in rats after oral or intravenous (i.v.) dosing of quinine was investigated. Female Wistar rats (wt 190-220 g) were used in two separate studies, i.e. oral and i.v. administration of quinine. The animals were divided into two groups, one served as control and the other group was pretreated with 25 mg/kg naringin once a day for 7 consecutive days before the pharmacokinetic study. On the study day, quinine (25 mg/kg) was administered to the rats by either the oral or i.v. route. Blood samples were collected at different times, up to 6 h after quinine administration. Plasma quinine concentration was assayed by HPLC. Pretreatment with naringin did not cause any significant change in the pharmacokinetics of quinine after the i.v. dose. However pretreatment with naringin led to a 208% increase in peak plasma concentration (Cmax), a 93% increase in time to reach Cmax (tmax), and a 152% increase in the area under the plasma concentration-time curve (AUC) of quinine after oral administration. Consequently, the oral bioavailability of quinine was significantly increased (p < 0.05) from 17% (control) to 42% after pretreatment with naringin. There was no significant difference in the elimination half-life (t(1/2)beta) of quinine between the two groups. These results suggest that pretreatment with the grapefruit flavonoid naringin is associated with increased oral bioavailability of quinine in rats.
authors.affiliation: Natural & Complementary Medicine Research, New Zealand 's National School of Pharmacy, University of Otago, Dunedin. hu.zhang@stonebow.otago.ac.nz
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: C W
authors.initials: CW
authors.lastname: Wong
authors.forename: P F
authors.initials: PF
authors.lastname: Coville
authors.forename: S
authors.initials: S
authors.lastname: Wanwimolruk
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000962:Antimalarials / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D002957:Citrus / Q000737:chemistry*; D065607:Cytochrome P-450 Enzyme Inhibitors; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D018565:Food-Drug Interactions; D006207:Half-Life; D016018:Least-Squares Analysis; D011803:Quinine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000962:Antimalarials; D065607:Cytochrome P-450 Enzyme Inhibitors; D005419:Flavonoids; D011803:Quinine